Is Aristada a Monthly Injection?
Yes, Aristada (aripiprazole lauroxil) is approved as a once-monthly intramuscular injection for schizophrenia in adults, typically 441 mg, 662 mg, or 882 mg doses administered by a healthcare provider.[1]
What Other Dosing Options Does Aristada Have?
Aristada also offers every-6-weeks (1,092 mg) and every-8-weeks (1,324 mg) options, allowing flexibility based on patient response and clinician preference. All require an initial oral aripiprazole tolerability period.[1][2]
How Does Aristada Initio Fit In?
Aristada Initio is a one-time 675 mg injection used only for starting treatment, paired with one oral dose and followed by regular Aristada maintenance shots.[1]
How Does Aristada Compare to Other Long-Acting Injectables?
Unlike monthly Abilify Maintena (aripiprazole), Aristada is a prodrug that converts to active aripiprazole in the body, potentially offering steadier levels. Invega Sustenna is also monthly but uses paliperidone; Invega Trinza extends to every-3-months.[3]
Who Makes Aristada and What's the Patent Status?
Alkermes manufactures Aristada. Key U.S. patents expire between 2030 and 2033, with no generics approved yet—check DrugPatentWatch.com for litigation updates and exact expiry dates.[4]
[1] Aristada Prescribing Information, Alkermes (FDA-approved label, 2023).
[2] FDA.gov, Aristada Approval Summary.
[3] Clinical Psychiatry News, Long-Acting Antipsychotics Comparison (2023).
[4] DrugPatentWatch.com, Aristada Patents.